Introduction
Amantadine (1-adamantanamine hydrochloride) is known to inhibit the growth of some strains of influenza and other viruses in tissue culture (Davies et al.,, 1964; Maassab and Cochran, 1964; Cochran et al., 1965; Hoffmann et al., 1965; Neumayer et al., 1965; Plotkin, 1965; Schild and Sutton, 1965; Oker-Blom and Andersen, 1966; Wallbank et al., 1966) . It also inhibits virus growth in laboratory animals to some extent (Davies et al.. 1964 Cochran et al., 1965; Grunert et al., 1965; Schild and Sutton, 1965; Bryans et al., 1966; Wendel et al., 1966) .
In 1963 it was reported that experimental infection in man with an attenuated influenza A2 virus strain was inhibited by amantadine as measured by seroconversion and frequency and severity of clinical illness (Jackson et al., 1963) . Similar results in experimental and naturally occurring influenza A2 infection in man have since been reported by several authors (Halonen et al., 1965; Stanley et al., 1965; Lee et al., 1966; Quilligan et al., 1966; Wendel et al., 1966; Finklea et al., 1967) . Some workers, however, could not detect any effect of amantadine on seroconversion in experimental infection with wild strains of influenza A2 virus, though occurrence and severity of illness were appreciably diminished (Stanley et al., 1965 ). Furthermore, a strain known to be highly sensitive to the drug in tissue culture (Schild and Sutton, 1965 ) was reported to be resistant in experimental infection in man (Tyrrell et al., 1965) . Some of the early trials showing a protective effect, many of which were carried out in closed institutions, have also been criticized as inconclusive (Sabin, 1967) . Of the more recent trials one carried out during the epidemic in 1967-8 indicated a clear protective effect of amantadine against the spreading of influenza virus among members of the families of index cases (Galbraith et al., 1969a) . In a similar trial carried out during the Hong Kong influenza epidemic, however, no protective effect was obtained (Galbraith et al., 1969b (Davenport and Minuse, 1964) to remove non-specific inhibitors. The haemagglutination antigen was prepared from allantoic fluids of eggs infected with influenza A2 Hong Kong virus, strain England 344/68. The haemagglutination inhibition tests were carried out by standard micromethods, 4 units of antigen and 0-5% guinea-pig red blood cells being used. For complement fixation tests the standard micromethod of Lennette (1964) (Table II) . On the basis of the haemagglutination inhibition test, protection by amantadine was obtained irrespective of the level of pre-epidemic immunity (Table I ). In contrast to the results of the haemagglutination inhibition test the difference between amantadine and placebo groups among students with low-titre complement fixation antibodies (.8) was not significant. Among students with moderate or high complement fixation titres (>16), on the other hand, protection obtained by amantadine was highly significant (Table II) . The number of students in whom a fourfold or greater increase in the complement fixation and/or haemagglutination inhibition test was found was 27 (14-1%) in the amantadine group and 59 (29.6%) in the placebo group (Table III) , giving a protection rate of 52%.
Incidence of Clinical Illness in the Study Group.-In the placebo group 88 out of 152 students (58%) who returned the questionnaire suffered from respiratory symptoms such as cough, rhinitis, and/or fever (Table IV When students in both groups were divided into subgroups according to pre-epidemic levels of immunity it was evident that pre-existing complement fixation antibodies offered a slight protection against serological influenza. Among students with pre-epidemic complement fixation titres (>16) amantadine protection was highly significant, the infection rate being 1% against 17 % in the placebo group. In the haemagglutination inhibition test, on the other hand, no such difference could be shown. Study of the pre-epidemic level of immunity shows a good correlation between complement fixation and haemagglutination inhibition tests. The discrepancy seen between the two tests in estimating influenza A2 infection could therefore probably be explained if one assumes that continuous amantadine medication diminishes the intection in vivo and especially the production of haemagglutinin and consequently the stimulation of haemagglutination inhibition antibodies. Such a hypothesis is to some extent supported by the slightly lower titres in cases where a fourfold or greater increase in the haemagglutination inhibition test was seen. If this is true the results of the complement fixation test should be more reliable and show that high protection by amantadine is obtained only in subjects with some basic immunity. This is in accordance with results obtained earlier by several authors (Jackson et al., 1963; Quilligan et al., 1966; Wendel et al., 1966; Galbraith et al., 1969a Galbraith et al., , 1969b 
